The Evolution of Healthcare: From Sickcare to Health Care
Adam Skali
I have experience on healthcare innovation and thrive in diverse, multidisciplinary teams. Together, let's unlock the future of transformative healthcare solutions.
The Age of Sickcare
The Gap Between Healthspan and Lifespan
Frailty and Social Determinants of Health
When Sick Care Isn’t Enough
Scientific Wellness: A Shift in Focus
The Age of Wellness
The Promise of Data and Personalized Medicine
What We Need for Wellness-Based Healthcare
Wellness Starts by Having Better Diagnostics
The age of Sickcare
In 1900, many countries around the world were grappling with severe public health crises, and were suffering from the effects of infectious diseases like pneumonia, tuberculosis, and polio. At this time, the global medical community was without vaccines, antibiotics, or reliable treatments, which left physicians largely powerless to combat these ailments.
Parents worldwide frequently faced the devastating reality of being informed by doctors that their child's condition was incurable. It wasn’t until relatively recently that we started being able to treat many of these diseases by using scientifically proven approaches. The most effective strategy to counteract these widespread infectious diseases was the enhancement of sanitation, such as the development of public water systems and waste disposal mechanisms and not, as is today, the use of specific drugs or treatments.
The discovery of the first vaccine is a landmark in medical history. Edward Jenner, made this breakthrough in 1796. Jenner observed that milkmaids who had contracted cowpox, a relatively mild disease, seemed immune to smallpox, a highly contagious disease estimated to have killed more than 300 million people since 1900 alone.
Building on this observation, Jenner developed the smallpox vaccine by inoculating individuals with cowpox virus, effectively creating immunity against smallpox. This pioneering work laid the foundation for modern vaccination practices and ultimately led to the “eradication” of smallpox, declared by the World Health Organization in 1980 as one of the greatest achievements in public health.
Since then, vaccination campaigns have successfully eliminated, in many regions, several diseases that were once common, such as diphtheria, tetanus, poliomyelitis, smallpox, measles, mumps, rubella, and Haemophilus influenzae type b meningitis. In the US in 1949, with the introduction of the combined diphtheria, tetanus toxoids, and pertussis vaccine, state and local health departments launched vaccination programs primarily targeting underprivileged children. The release of the Salk poliovirus vaccine in 1955 led to federally funded childhood vaccination programs.??
Another great example is the case of antibiotics. Alexander Fleming's discovery of penicillin in 1928 changed medicine and earned him the Nobel Prize in Physiology or Medicine in 1945. Fleming, a Scottish bacteriologist, accidentally stumbled upon penicillin while studying Staphylococcus bacteria. He noticed that a mold called Penicillium notatum produced a substance that killed bacteria, leading to the development of penicillin as the first antibiotic.
Penicillin's introduction transformed the treatment of bacterial infections, with an estimated 500 million lives saved by penicillin. and significantly reducing mortality rates from diseases such as pneumonia, tuberculosis, and bacterial meningitis among others.?????
And these techniques and approaches have worked quite well until recently, helping us reduce the number of deaths due to infections and certain diseases treatable with chirurgical procedures, and increase lifespan. But through this process now we are facing a different kind of problem, now the diseases we are facing aren’t only infections.
The Gap Between Healthspan and Lifespan
The global population has grown from 2.9 billion in 1950 to 7.8 billion in 2020, and average life expectancy has increased from 47 to 73 years over these seventy years. This growth in human lifespan has led to a shift in demographic structures, particularly highlighting an increase in people over 70 years old. As a result, more countries now see over one-fifth of their population in this older age group.
Historically, healthcare focused on infectious diseases prevalent among children, such as tuberculosis and pneumonia, influenced by the need to focus on immediate health solutions, and now the world is seeing a widening gap between lifespan—the total years lived—and healthspan—the years lived in good health. Currently, this gap is estimated at about nine years, with people spending a significant part of their lives dealing with illness. Simply extending life without addressing the onset or severity of diseases could worsen this gap.
Addressing this requires viewing health as the World Health Organization describes it: complete physical, mental, and social well-being, not just the absence of disease. Bridging the healthspan-lifespan gap will involve integrating scientific advancements with public and social initiatives.??
Frailty and Social Determinants of Health
Chronic diseases, often called lifelong or non-communicable diseases, are the primary cause of death and disability globally. They account for 40 million, or 71%, of the 56 million deaths each year and 79% of all disability-adjusted life years. The four main chronic diseases—cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases—cause 80% of these deaths.?
The economic impact of these diseases is massive, estimated at a $47 trillion loss over the past two decades. Notably, 58% of deaths related to chronic diseases occur in people over 70 years old.
Frailty, a significant decline across multiple body systems leading to increased vulnerability, worsens age-related outcomes. Despite its severe effects on quality of life, including increased disability, falls, hospitalizations, and death, frailty and related conditions remain under-recognized. Assessment tools identify frailty using the frailty phenotype—characteristics like weakness, slow walking, low activity, exhaustion, and weight loss—and the frailty index, which measures accumulated deficits.?
Frailty is prevalent in about 25% of those over 80 and is becoming more common in younger populations. It is exacerbated by poor lifestyle choices and disproportionately affects those with lower socioeconomic status and women, challenging the delivery of equitable healthcare.?
These are the so-called "social determinants of health" which encompass a range of factors including income, education, and local healthcare systems, which vary widely and make one's ZIP code a strong predictor of health outcomes. These determinants shape the conditions under which people are born, grow, live, work, and age, and include aspects like socioeconomic status, educational background, neighborhood and physical environment, employment, social support networks, and healthcare access.
These factors are interconnected, influencing health significantly. For example, individuals from lower socioeconomic backgrounds often encounter barriers such as poor living conditions and limited access to health-promoting resources, which can increase stress and reduce overall health, increasing the probability of developing chronic diseases.?
When Sick Care Isn’t Enough
The lag in quality of life is a recognized challenge that calls for prioritization of disease-free longevity. This single-disease focus effectively combatted infectious diseases but is inadequate for chronic conditions, which are complex and multifactorial, like cancer or autoimmune diseases. For example, drugs like adalimumab (Humira) manage symptoms for conditions such as rheumatoid arthritis and Crohn’s disease but do not cure them and carry risks like weakened immunity and potential heart failure.?
These drugs often fail to have a significant effect. They are costly, and for many of these drugs the effectiveness varies between patients, and symptoms often return quickly after stopping treatment, reflecting the ongoing challenge of addressing chronic diseases in healthcare. Drug developers focus on symptom relief because they are easier to measure and fix, when compared to highly complex diseases where we still don’t understand the main cause.??
Scientific Wellness: A Shift in Focus
Leroy Hood's concept of "Scientific Wellness" represents a shift from merely treating severe diseases to adopting earlier, more personalized interventions. This approach uses a systems perspective to enhance our understanding of health and disease progression, aiming for a proactive stance in healthcare.
The traditional reliance on "miracle molecules" to treat chronic diseases is becoming outdated. Many drugs only show modest results, and their effectiveness often barely surpasses that of placebos. While they may relieve some symptoms, the economic cost of these medications is high, and their overall effectiveness remains low. Pharmaceutical companies often need to offset high failure rates by increasing the prices of successful drugs, as seen in treatments for Alzheimer's disease, which are still largely ineffective.
For example, a collaborative study involving researchers from Germany, Austria, and the USA highlighted the overestimated effectiveness of common drugs, including antihypertensive medications and aspirin's minimal impact on preventing cardiovascular events.
The drugs listed include Abilify for schizophrenia, Nexium for heartburn, Humira for arthritis, Crestor for high cholesterol, Cymbalta for depression, Advair Diskus for asthma, Enbrel for psoriasis, Remicade for Crohn’s disease, Copaxone for multiple sclerosis, and Neulasta for neutropenia. For these top-selling drugs, the best outcome shows that only one in four patients sees benefits, while the least effective, benefits only one in twenty-five patients. Overall, less than 10% of patients see benefits, yet all risk serious side effects.
Despite advances, our healthcare system continues to grapple with the dual challenge of low medication effectiveness and high financial costs. Billions are spent on chronic diseases with minimal health improvements, leading to economic inefficiency. The system's preference for treatment over prevention exacerbates this issue, often disregarding innovations that do not promise immediate cost savings.?
Inconsistencies in insurance coverage, as people change jobs or insurance plans, discourage long-term health investments by providers. This is particularly evident in regions with Bismarck, out-of-pocket, or mixed-model healthcare systems, where dependence on private insurance influences treatment options. Additionally, the lack of comprehensive patient education on maintaining health — where doctors often receive minimal training in nutrition, exercise, sleep, and stress management — leads to missed or delayed diagnoses, especially in non-elderly patients.
The healthcare industry, which historically has done significant good, now struggles to meet the challenges of chronic diseases. Countries spend billions often without knowing who will benefit due to a lack of personalized medical data.??
Researchers must adopt more nuanced methodologies that consider a multitude of factors influencing treatment response, including genetic predispositions(natural differences in people’s DNA that can influence their health), various 'omics' data (such as genomics, proteomics, metabolomics), are like unique settings in a vast biological program, determining how we respond to medicines, and environmental influences
Initiatives like the NIH’s All of Us, which aims to sequence a million genomes, or UK’s Our Future Health, show us hope in a new kind of healthcare by working to create the tools for drug personalization. By comprehensively assessing these factors, researchers can gain deeper insights into the intricacies of individual responses to treatment, paving the way for more tailored and effective therapeutic interventions.
Leroy Hood’s Scientific Wellness
In his book “The Age of Scientific Wellness” the author, scientist and entrepreneur Leroy Hood, explains that future healthcare will focus on maintaining wellness and detecting early signs of disease to intervene before they fully manifest. This proactive approach involves continuous monitoring of health through advanced data analysis of genomes, lifestyles, and environments.
Key to this new paradigm is the integration of three types of data: genomic, phenomic, and digital health measurements. With these data, healthcare professionals can identify early signs of disease long before clinical symptoms appear. This will allow them to design personalized treatments to maintain health and prevent disease.
While through this approach not all diseases will be eradicated forever, if diseases do arise, their impact should be minimal, allowing for a life of sustained well-being. To achieve this, healthcare must shift from a reactive to a proactive stance, emphasizing prevention and personalized treatment based on comprehensive data analysis.
This vision for scientific wellness isn’t just about avoiding illness; it’s about optimizing life—a shift from merely treating symptoms to enhancing overall health.
The Age of Wellness
The goal of achieving a life largely free from disease and the effects of aging is within reach if we commit to making it happen. During the middle ages, and mainly due to Diclecian’s guild system, you could predict your future based on your parents’ lives. Farmers' children often became farmers, and traders' children followed into trade. But now, predicting even a few years ahead is challenging.
Technological progress in medicine is exponential. In 1950, medical knowledge doubled every fifty years; by 1980, every seven years; and by 2010, every three and a half years. In 2013 alone, there were 153 exabytes of global healthcare data, which increased to an estimated 2,314 exabytes by 2020. This rapid growth in medical knowledge will continue, highlighting the vast potential for medical advancement over the next fifty years.
The future of healthcare should therefore prioritize the maintenance and enhancement of wellness. It should aim not just at treating diseases but at preventing them before they occur. This proactive approach should center on keeping individuals in optimal health throughout their lives, rather than merely managing diseases as they manifest, through lifestyle changes, regular screenings, and vaccinations among other measures.
Emphasizing prevention over cure, this approach seeks to lessen the prevalence of costly chronic conditions like diabetes and heart disease, significantly lowering healthcare burdens. By focusing on preventive measures, the healthcare system helps individuals enjoy longer, healthier lives free from debilitating health issues, thereby boosting overall life satisfaction. Prevention also proves to be more cost-effective than treatment, allowing the savings to be reinvested in enhancing healthcare services and technologies.
By maintaining wellness from a young age, this strategy can increase the duration of life spent in good health, effectively matching longevity with quality of life.?
The promise of data and personalized medicine
Future medicine will allow us to stop chronic diseases we currently see as inevitable Although stopping diseases like Alzheimer's has been challenging, there are signs of a significant shift. For instance, personalized immunotherapies are changing cancer treatment, targeting the body’s defenses based on individual biology. These advances give experts hope for dramatically reducing deadly cancers with customized treatments.
Chronic diseases vary widely, from heart disease to autoimmune disorders like arthritis. Each has unique causes and progresses differently. However, they all worsen with age, leading us to our next focus: promoting healthy aging.
领英推荐
Many fear living more than 100 years because of the potential pain and loss of mental and physical functions. But if aging could be pain-free and active, perspectives change. It’s crucial that medicine not just extend life but enhance the quality of those extra years.?
The ideal health span should match our lifespan as closely as possible. Extending the time we live healthily increases our overall lifespan, allowing for a longer, healthier life. Aging is different from getting older; it’s about frailty, the decline in physical and mental abilities. While we can't stop time, we can slow aging by living healthier—eating well, exercising, managing stress, and avoiding toxins.
Emerging research even suggests the possibility of reversing aging, making us biologically younger. Slowing aging could allow people to enjoy a high-quality life into their nineties. However, who benefits from these advances raises ethical questions, as it could either reduce or worsen existing health disparities. The implications of extending health spans are profound, affecting social, economic, and political spheres.
To achieve this, we must improve how we track biological aging and assess the aging of vital organs and hormonal balances throughout different life stages. This means optimizing health across all life phases, ultimately leading to a natural and brief decline at life’s end, unlike the prolonged suffering many experience today.
What do We Need for Wellness Based Healthcare
To achieve this vision, we need to establish comprehensive health monitoring networks. These networks should be equipped with advanced knowledge of the complex, interrelated biological systems within our bodies. By leveraging this knowledge, we can gain insights that allow us to anticipate and counteract potential health issues well before they present any clinical symptoms.
Traditionally, doctors diagnose diseases based on subtle symptoms and their clinical intuition. However, in a truly wellness-centered healthcare system, the paradigm shifts dramatically. The mark of excellence in a physician would no longer be their ability to treat disease, but their effectiveness at preventing disease in the first place. A doctor whose patient develops symptomatic illness would consider it a professional failure.
"Precision prevention", is seldom tried due to high costs, limited data, and concerns about incorrect results. Handling medical data is challenging, much like diving into a complicated statistics problem. For centuries, doctors have dealt with varying data such as heart rates that range significantly and blood pressures that can swing from very low to very high. While common tests like those for cholesterol or blood sugar are routine, there are many more potential tests available, leading to countless data combinations.??
Technology now allows for extensive collection of health data through devices like fitness trackers, which record everything from steps and sleep quality to heart rate and stress levels continuously. The metrics for wellness that we should be tracking extend far beyond the simplistic notion of "how we feel." They include a comprehensive array of data points such as genomic information, phenomic patterns, and other digital health measures.?
These indicators collectively monitor hundreds of different biological systems and processes. If we begin collecting and analyzing these data from a state of health, we can develop predictive models that identify when an individual is likely to transition from a state of health to one of disease. These transitions are often so subtle that they escape our conscious detection.
Sensor networks are growing, enabling ongoing monitoring of health indicators like blood and saliva, not just occasionally but constantly. As these networks become more widespread, they will collect vast amounts of health data. To keep pace with these advancements, healthcare will require significant support and education so people can make informed choices and benefit from enhanced health systems.?
By implementing such measures, we can intervene earlier, more precisely, and in a less invasive manner than current practices allow, enhancing our ability to prevent diseases from developing into more severe, irreversible conditions. This proactive, preventive approach could make healthcare more effective and sustainable in the long run, aligning it with the principles of scientific wellness.
Wellness Starts by Having Better Diagnostics
While there has been remarkable progress in identifying numerous bio-markers associated with various diseases, there remains a notable dearth of independent evaluation of the reliability and accuracy of the tests used to detect these markers in biological samples.
The efficacy of personalized medicine hinges on the availability of precise diagnostic tests capable of identifying patients who would benefit from targeted therapies.
For instance, clinicians frequently rely on diagnostic tests to ascertain whether specific breast tumors exhibit overexpression of the human epidermal growth factor receptor type 2 (HER2), which not only correlates with a poorer prognosis but also predicts a favorable response to trastuzumab therapy. Approval of the HER2 test alongside the drug (as a "companion diagnostic") enables clinicians to tailor treatment to individual patients' needs.
Recent scientific progress is significantly enhancing medical care through personalized medicine, focusing on genetics, transcriptomics, proteomics, spatial transcriptomics, metabolomics, and advanced imaging.
The Importance of Genomics in Healthcare
Healthcare today is increasingly influenced by genomic science, a field that has seen rapid advancements and growing accessibility. Initially, decoding the first human genome was a monumental task that required substantial resources, involving hundreds of scientists. Today, however, genome sequencing has become a routine procedure that anyone can access for a few hundred dollars and have results within days.
Our genome contains a wealth of information about the biological systems operating within our body. It is utterly unique to us, offering a detailed map of your genetic makeup. As scientific understanding progresses, this genomic information is increasingly used to tailor medical care to individual needs, heralding a new era of personalized medicine. This approach promises not only potential cures for genetic disorders but also offers strategies for maintaining health throughout one's lifetime.
The availability of genomic data is changing the way healthcare is delivered. Instead of a one-size-fits-all approach based on average outcomes from clinical trials, treatments and preventative measures can be customized. Blood tests, for instance, including markers like LDL or HDL cholesterol, can be interpreted through the lens of your personal genomic blueprint. Understanding our genetic risk profiles enables a highly personalized healthcare strategy, providing insights into which lifestyle choices and medical treatments are likely to be most effective for us.
Moreover, the field of genomics is not just about understanding risk but also about the potential to actively intervene. Advanced genetic engineering techniques, such as those involving CRISPR, offer the possibility of editing the genetic code to prevent inherited diseases. The science for gene editing is advancing rapidly, and we are approaching a future where diseases like Huntington’s or cystic fibrosis could potentially be corrected before birth, effectively eliminating these conditions from the genetic line.
In addition to genetic editing, assisted reproductive technologies like in vitro fertilization (IVF) provide opportunities for individuals to prevent the transmission of dominant genetic diseases to their children.??
As we continue to unravel the complexities of the human genome, the integration of genomic data into everyday healthcare practices is likely to become more prevalent, offering unprecedented opportunities for disease prevention and health optimization. This shift towards a more informed, personalized healthcare system promises not only to enhance the quality of life but also to extend it, making the most of the advancements in genetic science.
The Answer is Usually Multifaceted
Each of these approaches offers insights into what is happening, but which one of them is the best predictor can change for each disease, and many a time the best answer is to mix them as in the end what each of these techniques is giving us is only a probability. For example, breast MRI stands out as one of the most effective methods for detecting breast cancer and accurately assessing tumor response. By combining MRI findings with clinical tumor measurements, some studies achieved the highest accuracy in predicting pathologic response post-chemotherapy.
Radiogenomics offers another valuable application by correlating MRI features of breast cancer with genomic assays, which provide prognostic scores indicating the risk of cancer recurrence.? Studies have shown correlations between computer-extracted MRI features and gene expression, revealing insights into tumor behavior and recurrence risk. Multigene assays and microarray assays analyze breast cancer expression profiles to assess recurrence risk. MRI-derived qualitative data may serve as a potential imaging biomarker for predicting breast cancer recurrence risk.
An increasingly popular approach is deep phenotyping. Deep phenotyping is an extensive and detailed approach to understanding a patient's health by analyzing a wide range of data types. It goes beyond just looking at someone's genetic information to include their clinical history, behaviors, lifestyle choices, and even data collected from their use of digital devices like smartphones or wearables. This method aims to create a comprehensive profile of a person's health status and disease risk factors.
In the context of personalized oncology, it allows doctors to consider not just the biological aspect of a tumor's genetics but also how various other factors—like a patient's environment, daily habits, and personal health practices—might influence the effectiveness of a treatment. For example, data on a patient's physical activity levels, collected through a smartphone app, or their dietary habits, gathered from an online survey, could provide insights into how well they might respond to a specific cancer therapy.?????
Digital Twins in Healthcare
A digital twin in healthcare is a digital version of a person that can simulate treatment options, monitor health, and predict future health changes. This is done by using a wide range of data, including clinical and genetic information, as well as environmental and social factors. A digital twin has three main parts: a real person, their digital counterpart, and a connection that allows information to flow both ways, impacting both the real and digital versions. This interaction can cover all scales, from tiny details to the whole body, and lasts a lifetime. A digital twin should be personalized, connected, interactive, full of information, and make a difference.
Computational modeling and artificial intelligence (AI) or machine learning (ML) are key in creating digital twins, helping with disease understanding, drug development, and personalized medicine. However, a true digital twin involves more than just these technologies—it requires a real and virtual version of a person or part of the body to be connected and offer personalized insights.
Different digital twins serve various purposes. For example, ones that focus on specific organs might use detailed imaging data, while those for understanding diseases might combine molecular data with clinical information. These models are crucial for everything from predicting how devices like pacemakers will work to understanding drug effects on diseases. The specific data and analytics used in each model vary, highlighting the importance of these tools in enhancing healthcare and medicine.
The essence of a digital twin lies in its five foundational characteristics: personalized (tailored to the individual), connected (integrated within broader health systems), interactive (capable of receiving and responding to inputs), informative (providing valuable health insights), and impactful (effecting meaningful health outcomes). By amalgamating data from diverse sources—ranging from omics (genomics, transcriptomics, proteomics) to environmental factors and medical imaging—Digital Twins provide a comprehensive and dynamic portrayal of an individual's health profile. This multidimensional approach enables clinicians and researchers to delve deeper into the intricate interplay between genetic predispositions, environmental influences, and disease states.
Omics data, elucidating molecular signatures unique to each individual, empowers clinicians to discern genetic variations, predict treatment responses based on individual genetic makeup, and tailor interventions to target specific molecular pathways implicated in disease progression. Moreover, the integration of environmental factors—such as lifestyle choices, dietary habits, toxin exposure, and socio-economic determinants—into Digital Twins offers a holistic understanding of an individual's health status. This comprehensive approach informs treatment decisions, empowering patients to adopt lifestyle modifications conducive to optimal health outcomes.
Medical imaging serves as a cornerstone in disease characterization and monitoring. By incorporating imaging data—such as MRI, CT scans, and PET scans—into Digital Twins, clinicians gain insights into anatomical structures, detect abnormalities, and monitor disease progression in real-time. This visual representation enhances diagnostic accuracy, facilitates treatment planning, and guides personalized treatment strategies tailored to individual patient needs.
For example, a digital twin of the liver could help surgeons plan complex procedures by simulating different surgical approaches, or a digital twin of a tumor might allow oncologists to test various treatment combinations to find the most effective strategy for a particular patient's cancer type. Beyond individual treatment planning, digital twins offer the potential to revolutionize public health strategies by modeling the spread of infectious diseases within a community or evaluating the impact of environmental changes on population health.
For instance, the application of digital twins in cardiac care has seen the development of heart models that utilize detailed imaging data to predict how mechanical interventions, such as pacemakers and stents, will perform in an individual's unique cardiac system. This organ-specific application contrasts with disease-focused digital twins, which amalgamate molecular data with patient health records to offer insights into the effectiveness of pharmaceutical treatments, particularly how drugs may interact with an individual's specific biological makeup to combat diseases like cancer or diabetes.
Modeling human health in digital twins is complex, given the dynamic nature of human biology and behavior. It's challenging to capture every influencing factor accurately. Advances in computing power, big data, and IoT devices promise more sophisticated and useful digital twins, while technologies like 5G and blockchain offer prospects for faster, secure data handling. Nonetheless, ensuring that digital twins are accessible and do not widen health disparities remains a significant concern, pointing to the need for ethical guidelines and equitable healthcare practices in their development and use.?????
Data alone isn’t enough
While the advantages of increasing the amount of data to which we have access is essential, it also comes with a set of limitations. There is a saying that data is gold, but it is actually more similar to a diamond in the rough, it only has value when we can extract patterns, correlations and use them to make predictions.
And unfortunately, the human mind alone, no matter how many people we put to the task, might not be enough to handle the overwhelming amount of data generated by modern medicine. The data complexity exceeds human understanding and requires significant computational help. Artificial Intelligence (AI) will be crucial in making sense of this data and providing valuable insights to doctors.
Doctors have traditionally looked for patterns in data, and AI excels at this on a much larger scale. It can identify patterns across vast datasets quickly, similar to conducting an internet search to find correlations between data and diseases. As these connections are confirmed, the process becomes more focused on larger groups, increasing the demand for processing power. However, our ability to handle this data, in terms of both computing and storage, has been growing exponentially and will continue to do so.
AI is already aiding institutions like Harvard Medical School by offering prediagnostic advice and checking diagnoses to prevent costly and harmful errors. In the future, AI will not just analyze complex data sets but will also organize this data into functional systems that cover all levels of biological organization—from molecules to the entire body—and apply it to various population subsets. This will enable highly personalized medicine.
AI’s scope extends beyond individual health, evaluating genomic data, social networks, and environmental factors to enhance our collective health prospects.
Next Steps
The translation of these scientific advancements into practical benefits for patients poses a challenge. Realizing the full potential of this approach extends beyond technological advancements—it demands a fundamental shift in mindset across regulatory bodies, pharmaceutical enterprises, and clinical settings alike. Embracing the principles of personalized medicine requires a departure from conventional trial methodologies and a concerted effort to integrate it into the fabric of healthcare practice.
Scientists must determine which genetic and/or metabolic markers hold the most relevance for medical decision-making and devise strategies to mitigate the potential side effects of gene-based therapies. Additionally, efforts are required to establish links between the data and responses to drug treatments. On the regulatory front, striking the right balance between regulations for genetic tests to safeguard patients' interests while fostering innovation is crucial.
For example, a laboratory developed a test claiming to identify patients who are more likely to respond to rituximab treatment, but the FDA had not evaluated the scientific basis for this assertion. Despite this, healthcare providers may use the test results to guide treatment decisions. This circumvents the established approval process designed to safeguard patients, compromises the availability of accurate treatment information for physicians, and diminishes the likelihood of adopting new therapeutic-diagnostic strategies.
To address this issue, there is a need for streamlining and clarification of the regulatory pathways that manufacturers must follow for their claims, including stipulating when a companion diagnostic must be approved or cleared concurrently with the therapy. Diagnostic tests are not infallible, primarily because most gene mutations do not consistently predict clinical outcomes. Consequently, clinicians must grasp the sensitivity and specificity of new diagnostics. The objective is to establish an efficient review process that yields diagnostic-therapeutic approaches clinicians can trust, while enabling companies to make specific.
Moreover, making precision medicine mainstream requires a fundamental shift in the patient-doctor relationship towards a model that prioritizes individualized care. Personalized medicine requires empowering patients by directly involving them in the treatment decision-making process and offering personalized treatment options tailored to their unique needs and characteristics. As patients become more engaged in their healthcare decisions, healthcare providers must adapt to accommodate individual patient preferences and circumstances, ultimately leading to improved healthcare outcomes and patient satisfaction.?
?References:
Hood, L., & Price, N. D. (2023). The Age of Scientific Wellness: Why the Future of Medicine Is Personalized, Predictive, Data-Rich, and in Your Hands. Belknap Press
G. M. Bartelds et al., “Development of Antidrug Antibodies against Adalimumab and Association with Disease Activity and Treatment Failure during Long-Term Follow-Up,” Journal of the American Medical Association 305 (2011): 1460–1468.
Alzheimer’s Association, “Alzheimer’s Disease Treatment Horizons,” updated October 2019,??
Rinke de Wit, T. F., Janssens, W., Antwi, M.. (2022, November 28). Digital health systems strengthening in Africa for rapid response to COVID-19. Frontiers in Health Services, 2, 987828. https://doi.org/10.3389/frhs.2022.987828
Artiga, S., & Hinton, E. (2018). Beyond health care: The role of social determinants in promoting health and health equity. Kaiser Family Foundation. Retrieved from https://resource.nlm.nih.gov/101740257
?Hamburg, M. A., & Collins, F. S. (2010). The Path to Personalized Medicine. New England Journal of Medicine, 363, 301-304.
Schork NJ. Personalized Medicine: Time for One-Person Trials. Nature 2015; 520: 609-611.
Puska, P., & Jaini, P. (2020). The North Karelia Project: Prevention of Cardiovascular Disease in Finland Through Population-Based Lifestyle Interventions. American Journal of Lifestyle Medicine, 19, 495-499.
Artiga, S., & Hinton, E. (2018). Beyond health care: The role of social determinants in promoting health and health equity. Kaiser Family Foundation. Retrieved from https://resource.nlm.nih.gov/101740257
Katsoulakis, E., Wang, Q., Wu, H., et al. (2024). Digital twins for health: A scoping review. npj Digital Medicine, 7, 77. https://doi.org/10.1038/s41746-024-01073-0
Garmany, A., Yamada, S., & Terzic, A. (2021). Longevity leap: Mind the healthspan gap. NPJ Regenerative Medicine, 6(1), Article 57. https://doi.org/10.1038/s41536-021-00169-5
Control of Infectious Diseases. (1999). JAMA, 282(11), 1029-1032. https://doi.org/10.1001/jama.282.11.1029
Editing aided by ChatGPT
That shift from infectious diseases to chronic conditions is crucial for maximizing overall wellness, right? Adam Skali